<DOC>
	<DOCNO>NCT01426763</DOCNO>
	<brief_summary>The objective study : 1 . Evaluate safety tolerability subcutaneously administer CINRYZE recombinant human hyaluronidase ( rHuPH20 ) subject hereditary angioedema ( HAE ) previously participate CINRYZE Study 0624-200 ( NCT01095497 ) 2 . Characterize pharmacokinetics pharmacodynamics subcutaneously administer CINRYZE rHuPH20 3 . Assess immunogenicity CINRYZE follow subcutaneous ( SC ) administration CINRYZE rHuPH20</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacology Subcutaneous Administration CINRYZE With Recombinant Human Hyaluronidase</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>To eligible protocol , subject must : 1 . Provide informed consent/assent , appropriate . 2 . Have previously participate CINRYZE Study 0624200 complete subcutaneous therapy period study . 3 . During 3 consecutive month prior screen , history le 1 HAE attack per month ( average ) require treatment C1 INH therapy blood product . 4 . Agree avoid his/her known HAE trigger study best his/her ability . To eligible protocol , subject must : 1 . Have receive C1 INH therapy blood product treatment prevention HAE attack within 14 day prior first dose study drug . 2 . Have receive ecallantide ( Kalbitor ) , icatibant ( Firazyr ) , antifibrinolytics ( e.g. , tranexamic acid ) within 14 day prior first dose study drug . 3 . Have change ( start , stop , change dose ) androgen therapy ( e.g. , danazol , oxandrolone , stanozolol , testosterone ) within 14 day prior first dose study drug . 4 . If female , start take change dose hormonal contraceptive regimen hormone replacement therapy ( i.e. , estrogen/progestin contain product ) within 3 month prior first dose study drug . 5 . Have history abnormal blood clotting . 6 . Have history allergic reaction product contain C1 INH blood product . 7 . Have know allergy hyaluronidase ingredient rHuPH20 . 8 . Be pregnant breastfeeding . 9 . Have receive investigational study drug within 30 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HAE</keyword>
	<keyword>C1 esterase inhibitor</keyword>
	<keyword>C1 INH</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>hyaluronidase</keyword>
	<keyword>rHuPH20</keyword>
</DOC>